Alfred N. Nijkerk
Founder at VenGen BV
Profile
Alfred Nijkerk holds an MSc in Pharmacy and a PharmD from Utrecht University.
After a few years as an Industrial Pharmacist at Byk Netherlands (currently Altana Pharma), he founded three specialized pharmaceutical contract manufacturing companies (two of which he co-founded together with Bart van den Berg).
In 2001 he founded VenGen, and since then he also co-founded Lactive BV , Porifarma BV, and to-BBB.
Alfred Nijkerk is Chief Business Officer of to-BBB.
Alfred N. Nijkerk active positions
| Companies | Position | Start |
|---|---|---|
VenGen BV
 VenGen BV Investment ManagersFinance VenGen BV is an independent venture capital investment firm based in Amsterdam. VenGen was founded in 2001 by Alfred Nijkerk, Bart van den Berg and Jaap Blaak. The firm's name is short for 'venture genesis' or rather the origin of venture. The firm provides venture capital to scientists and entrepreneurs operating in the field of life sciences. | Founder | 2001-07-21 |
UbiQ Bio BV
 UbiQ Bio BV Pharmaceuticals: MajorHealth Technology UbiQ Bio BV specializes in the ubiquitin related reagents, peptides and assays. The firm focuses on pharma companies and academic research labs. The company was founded by by Huib Ovaa and Farid El Oualidin in 2010 and is headquartered in Amsterdam, the Netherlands. | Chief Executive Officer | 2011-07-24 |
Former positions of Alfred N. Nijkerk
| Companies | Position | End |
|---|---|---|
Lactive BV
 Lactive BV Food: Major DiversifiedConsumer Non-Durables Lactive is an innovative food ingredients company that develops technology to produce and isolate specialty proteins from milk. Lactive focuses on a class of proteins naturally present in milk; immunoglobulins. These proteins have the particular bio activity to improve resistance of infants, hospitalized persons and elderly. The company was founded in 2005 by Herman de Boer, Alfred Nijkerk, and Willem Fokkema and is headquartered in Velp, The Netherlands. | Founder | 2011-07-19 |
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Founder | - |
Photonics Healthcare BV
 Photonics Healthcare BV Medical SpecialtiesHealth Technology Photonics Healthcare BV engages in the development of medical devices for monitoring mitochondrial function in to clinical practice. It offers Comet monitor, which allows doctors to optically measure the oxygen in the mitochondria inside a patient's cells. The company was founded by Egbert Gezinus Mik, Michael Münker, and Alfred N. Nijkerk in October 2009 and is headquartered in Utrecht, the Netherlands. | Founder | - |
ViciniVax BV
 ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Chief Executive Officer | - |
Training of Alfred N. Nijkerk
| University of Utrecht | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
VenGen BV
VenGen BV Investment ManagersFinance VenGen BV is an independent venture capital investment firm based in Amsterdam. VenGen was founded in 2001 by Alfred Nijkerk, Bart van den Berg and Jaap Blaak. The firm's name is short for 'venture genesis' or rather the origin of venture. The firm provides venture capital to scientists and entrepreneurs operating in the field of life sciences. | Finance |
Lactive BV
Lactive BV Food: Major DiversifiedConsumer Non-Durables Lactive is an innovative food ingredients company that develops technology to produce and isolate specialty proteins from milk. Lactive focuses on a class of proteins naturally present in milk; immunoglobulins. These proteins have the particular bio activity to improve resistance of infants, hospitalized persons and elderly. The company was founded in 2005 by Herman de Boer, Alfred Nijkerk, and Willem Fokkema and is headquartered in Velp, The Netherlands. | Consumer Non-Durables |
ViciniVax BV
ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Health Technology |
UbiQ Bio BV
UbiQ Bio BV Pharmaceuticals: MajorHealth Technology UbiQ Bio BV specializes in the ubiquitin related reagents, peptides and assays. The firm focuses on pharma companies and academic research labs. The company was founded by by Huib Ovaa and Farid El Oualidin in 2010 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Photonics Healthcare BV
Photonics Healthcare BV Medical SpecialtiesHealth Technology Photonics Healthcare BV engages in the development of medical devices for monitoring mitochondrial function in to clinical practice. It offers Comet monitor, which allows doctors to optically measure the oxygen in the mitochondria inside a patient's cells. The company was founded by Egbert Gezinus Mik, Michael Münker, and Alfred N. Nijkerk in October 2009 and is headquartered in Utrecht, the Netherlands. | Health Technology |
to-BBB technologies BV
to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Alfred N. Nijkerk
